Table 3.
Meta-Analyses of Randomized Controlled Trials of Vasoactive Drugs for Reduction of Mortality
| Meta-Analysis Studies | Number of Studies | Drug Combinations | Odds Ratio (OR) or Risk Ratio (RR) for All-Cause Mortality or Survival (95% Confidence Interval) | Heterogeneity (I2) | Test for Overall Effect (P Value) | Studies Included in the Meta-Analysis |
|---|---|---|---|---|---|---|
| Fabrizi (2009)96 | 5 | Terlipressin vs. placebo | OR=2.06 [0.94, 4.54]* | 55% | 0.07 | Hadengue (1998)106, Solanki (2003)112, Sanyal (2008)109, Martin-Llahi (2008)107, Neri (2008)108 |
| Gluud (2010)99 | 6 | Vasoconstrictor drug alone or with albumin vs. no intervention or albumin | RR=0.82 [0.70, 0.96] | 0 | Not reported | Yang (2001)119, Solanki (2003)112,Pomier-Lyrargues (2003)120, Sanyal (2008)109, Martin-Llahi (2008)107, Neri (2008)108 |
| Not reported | Terlipressin alone or with albumin vs. no intervention or albumin | RR=0.80 [0.66, 0.97] | Not reported | Not reported | Not reported | |
| Not reported | Terlipressin+albumin vs. albumin | RR=0.81 [0.68, 0.97] | Not reported | Not reported | Not reported | |
| Not reported | Terlipressin vs. no intervention | RR=0.13 [0.01, 2.10] | Not reported | Not reported | Not reported | |
| Not reported | Octreotide+albumin vs. albumin | RR=0.86 [0.58, 1.30] | Not reported | Not reported | Not reported | |
| Sagi (2010)102 | 3 | Terlipressin vs. control/placebo | RR=1.85 [1.00, 3.41]* | 0% | 0.05 | Sanyal (2008) 109, Martin-Llahi (2008)107, Neri (2008)108 |
| Gluud (2012)100 | 5 | Terlipressin alone or with albumin vs. no intervention or albumin | RR=0.75 [0.59, 0.97] | 39% | 0.028 | Yang (2001)119, Solanki (2003)112,Sanyal (2008) 109, Martin-Llahi (2008)107, Neri (2008)108 |
| Mattos (2016)101 | 4 | Terlipressin vs. noradrenaline | RR=1.04 [0.84, 1.30]* | 0% | 0.70 | Alessandria (2007)103, Sharma (2008)110, Singh (2012)111, Ghosh (2013)105 |
| Gifford (2017)98 | 4 | Terlipressin+/-albumin vs. no intervention/placebo+/-albumin | RR=0.79 [0.63, 1.01] | 53% | 0.06 | Solanki (2003)112, Sanyal (2008)109, Neri (2008)108, Boyer (2016)117 |
| 1 | Terlipressin infusion vs. terlipressin bolus | RR=1.58 [0.86, 2.91] | Not applicable | 0.14 | Cavallin (2016)92 | |
| 3 | Terlipressin vs. noradrenaline | RR=1.04 [0.74, 1.47] | 0% | 0.81 | Alessandria (2007)103, Sharma (2008)110, Singh (2012)111 | |
| 2 | Terlipressin+albumin vs. dopamine+standard care | RR=0.98 [0.76, 1.26] | 0% | 0.87 | Silawat (2011)114, Srivastava (2015)121 | |
| 1 | Noradrenaline+albumin vs. octreotide+midodrine+albumin | RR=1.50 [0.60, 3.78] | Not applicable | 0.39 | Tavakkoli (2012)113 | |
| Facciorusso (2017)97 | 6 | Terlipressin vs. placebo | OR=0.65 [0.41, 1.05] | 20% | 0.08 | Solanki (2003)109, Sanyal (2008)109, Martin-Llahi (2008)107, Neri (2008)108, Zafar (2012)116, Boyer (2016)117 |
| 4 | Terlipressin vs. noradrenaline | OR=1.02 [0.46, 2.28] | 0% | 0.95 | Alessandria (2007)103, Sharma (2008)110, Singh (2012)111, Indrabi (2013)115 | |
| 1 | Terlipressin vs. dopamine+furosemide | OR=1.00 [0.18-5.67] | Not applicable | 1.00 | Srivastava (2015)121 | |
| 1 | Terlipressin vs. octreotide+midodrine | OR=0.90 [0.27, 3.05] | Not applicable | 0.87 | Cavallin (2015)104 | |
| 1 | Noradrenaline vs. octreotide+midodrine | OR=2.50 [0.29, 21.40] | Not applicable | 0.40 | Tavakkoli (2012)113 |
*
Survival was reported instead of mortality.